San Diego, CA -- (SBWIRE) -- 07/02/2013 -- An investigation on behalf of investors in Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) shares was announced concerning whether a takeover of Onyx Pharmaceuticals, Inc. would be unfair to investors in NASDAQ:ONXX shares.

Investors who purchased shares of the Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and currently hold any of those NASDAQ:ONXX shares have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm is at an early stage and concerns whether a potential takeover would be unfair to Onyx Pharmaceuticals investors.

On Jun. 30, 2013, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) confirmed that it has received and rejected an unsolicited proposal from Amgen Inc. to acquire all of Onyx Pharmaceuticals’ outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions.

Given that NASDAQ:ONXX shares jumped after the announcement in the open market to $131.97 per share, the investigation a law firm concerns whether the Onyx Pharmaceuticals Board of Directors will undertake an adequate sales process, adequately shop the company before entering into any transaction, maximize shareholder value by negotiating the best price, and act in the shareholders' best interests in connection with the proposed sale.

Those who are current investors in Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and purchased their NASDAQ:ONXX shares prior to the announcement, have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Joelle Day
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com